Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04245865 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer

Study acronym: Toco-CoR
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study completion date: Dec 2025 to Dec 2026v14
  2. Primary completion date changed from estimate of Mar 2025 to Mar 31, 2025
    • Study completion date: Mar 2025 to Dec 2025
    v13
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 74 to confirmed 83
    • Primary and study completion dates: Oct 2024 to Mar 2025
    • Site details revised
    v12
  4. Primary and study completion dates: Oct 2023 to Oct 2024v11
  5. 4 versions Re-verified since Nov 23, 2021, no change to tracked fieldsv7-v10
Show 5 earlier versionsHide 5 earlier versions
  1. Study completion date: Dec 2026 to Oct 2023v6
  2. Re-verified, no change to tracked fieldsv5
  3. Start date changed from estimate of Jun 2020 to Jun 26, 2020v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  5. Start date: Mar 2020 to Jun 2020v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This double blind, randomized phase II trial will investigate whether the addition of tocotrienol will improve the effect and lower the toxicity of standard chemotherapy and bevacizumab. Half of the patients will receive tocotrienol and the other half placebo. Treatment is planned for a period of maximum six months and will be discontinued earlier in case of progression or unacceptable toxicity.
Trial Details
NCT Number NCT04245865
Lead Sponsor Vejle Hospital
Conditions
(from sponsor)		 Colorectal Cancer Metastatic
Related terms Colorectal Neoplasms
Enrollment 83 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov